Breath Analysis Technique to Diagnose Pulmonary Embolism
Pulmonary Embolism
About this trial
This is an interventional other trial for Pulmonary Embolism focused on measuring Capnography, Thromboembolism, Arthroplasty, D-dimer
Eligibility Criteria
Phase I Inclusion Criteria: Experienced or is scheduled for at least one of the following: Hip or knee replacement surgery Hip or acetabular fracture surgery Pelvic fracture Decompression for spinal stenosis surgery Scoliosis corrective surgery Craniotomy surgery for brain tumor Surgery for any of the following cancers: bladder, colon (including caecum and rectum), kidney, ovary, pancreas, or uterus Phase I Exclusion Criteria: Currently undergoing treatment for PE or has received treatment for PE in the 4 weeks prior to study entry Hospitalized for fewer than 2 days Anatomic abnormality that would prevent use of a mouthpiece Living situation that makes follow-up difficult (e.g., homeless, incarcerated) Phase II Inclusion Criteria: Clinical suspicion of PE with signs or symptom suggestive of PE within 24 hours of presentation and at least one risk factor for PE, as defined under the criteria as outlined in this protocol CTA of pulmonary arteries ordered by clinical care providers 18 years or older or an emancipated 17 year old Written informed consent Phase II Exclusion Criteria: Hemodynamic instability, including patients with a systolic blood pressure less than 90 mm Hg Severe respiratory distress or the inability to breathe room air without the sensation of severe dyspnea Pulse oximetry reading that declines more than 10% when exogenous oxygen is discontinued with accompanying worsening or new dyspnea Intubated Cannot breathe through the mouth owing to anatomic, physical or mental limitation No fixed address, no telephone number, are from out of town or have other reason to suspect difficulty with follow-up Incarceration Known active tuberculosis Prior PE or DVT with history of medical noncompliance with oral anticoagulation therapy based upon a history of unplanned subtherapeutic INR measurements (less than 1.5) Active PE within previous 6 months and currently under treatment with anticoagulation Pregnant Disallowed medications: treatment with any fibrinolytic agent within 48 hours prior to enrollment
Sites / Locations
- Carolinas Medical Center
Arms of the Study
Arm 1
Experimental
BreathScreen PE + D-dimer
CO2/O2 ratio will be measured using the Breath Screen PE device. D-dimer levels will also be collected.